Novo reports positive Phase III REDEFINE 1 results for CagriSema

​

Novo Nordisk has reported post hoc findings from the Phase III REDEFINE 1 trial evaluating its investigational combination therapy CagriSema in adults with overweight or obesity.

The post Novo reports positive Phase III REDEFINE 1 results for CagriSema appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.